Specialty Pharmacy

African American women account for 62% of women diagnosed with HIV.

Top news of the week in oncology and cancer drug development.

Ocrelizumab may effectively treat patients with relapsing multiple sclerosis and primary progressive multiple sclerosis.

Top articles of the week from Specialty Pharmacy Times.

Ninety-three percent of women reported at least 1 adverse event from breast cancer treatment.

Scientists used a novel approach for imaging the movement of immune cells in mouse models of RA.

Immunotherapy also found to prolong life in patients with bladder cancer.

Young and middle-aged adults with colon cancer are 2 to 8 times more likely to receive postoperative chemotherapy.

Computer algorithm for skin cancer matched performance of human dermatologists.

Cancer may be stopped by depriving cells of vital nutrients.

Repetitive transcranial magnet stimulation shows promise treating symptoms of MS.

Application pulled for biosimilar that treats neutropenia.

Congress, regulators, and the media expected to place pressure on pharmacy benefit managers in the coming months.

TNFis improve the burden of comorbidity associated with RA.

Combination treatment prior to surgery changes the clinical significance of growth factors as potential biomarkers.

Prevention programs, HIV testing, and easier access to treatment are all areas that need to be addressed.

Fake hepatitis C pills are entering the distribution network through back-channel wholesalers.

Teva loses patent infringement litigations for Copaxone.

Top news of the day from across the health care landscape.

President Donald Trump signed an executive order this week that could have direct implications for the FDA.

Would federal funding cuts to the Ryan White Care Act be "devastating" to the HIV-positive population?

Incidence of sleep apnea is 75% higher in patients with rheumatoid arthritis.

Gene may induce a broad-spectrum cellular response against infectious diseases.

Ductal carcinoma in situ influences risk of all-cause mortality.

RG-101 placed on clinical hold last year after a second reported case of jaundice.

Top news of the day from across the health care landscape.

HIV non-disclosure not found to have an adverse impact on depression or anxiety symptoms.

Risk factor may serve as a future drug target for ulcerative colitis.

Availability of new therapies and cost concerns create barriers for cancer patients.

Daniel P. Kus, BS Pharm, RPh, discusses how specialty pharmacies can help patients manage out-of-pocket drug spending.